Page 88 - 《中国药房》2021年8期
P. 88

V/V)]对贝林司他和杂质的溶解性均较好,且对其测定                               sion[J]. Mol Pharmacol,2019,95(3):324-334.
        无干扰,因此选择流动相B作为溶剂。                                   [ 8 ]  POH C,ARORA M,GHUMAN S,et al. Belinostat in re-
        3.3 检测波长的选择                                              lapsed/refractory T-cell large granular lymphocyte leuke-
            本研究预实验发现,贝林司他及各杂质在220 nm波                            mia[J]. Acta Haematol,2020,29(1):1-5.
        长附近均有较大吸收,因此选择220 nm作为贝林司他有                         [ 9 ]  STEWART A,YATES I,MUDIE D,et al. Mechanistic
                                                                 study of belinostat oral absorption from spray-dried disper-
        关物质的检测波长。
                                                                 sions[J]. J Pharm Sci,2019,108(1):326-336.
            综上所述,本研究所建立的 HPLC 法能使贝林司他
                                                            [10]  LIEW W C,SUNDARAM G M,QUAH S,et al. Belino-
        的主峰与杂质A、B、C、D、F、G、H得到良好分离。同时,
                                                                 stat resolves skin barrier defects in atopic dermatitis by tar-
        破坏试验结果显示,贝林司他降解过程中质量基本稳
                                                                 geting the dysregulated miR-335:SOX6 axis[J]. J Allergy
        定,且主峰与各降解杂质均能达到良好分离。经检验,
                                                                 Clin Immunol,2020,146(3):606-620.
        本研究中所使用的 3 批贝林司他原料药中仅存在杂质                           [11]  MARAMPON F,DI NISIO V,PIETRANTONI I,et al.
        A、D、H,且含量均较低,杂质 B、C、F、G 均未检出。可                           Pro-differentiating and radiosensitizing effects of inhibi-
        见,本研究成功建立了测定贝林司他中有关物质含量的                                 ting HDACs by PXD-101(belinostat)in in vitro and in
        方法,且方法准确、专属性好。                                           vivo models of human rhabdomyosarcoma cell lines[J].
        参考文献                                                     Cancer Lett,2019,461(1):90-101.
        [ 1 ]  LU P,GU Y,LI L,et al. Belinostat suppresses cell proli-  [12]  ZHENG S,GUO S,ZHONG Q,et al. Biocompatible bo-
             feration by inactivating Wnt/β-catenin pathway and pro-  ron-containing prodrugs of belinostat for the potential
             motes apoptosis through regulating PKC pathway in   treatment of solid tumors[J]. ACS Med Chem Lett,2018,9
             breast cancer[J]. Artif Cells Nanomed Biotechnol,2019,  (2):149-154.
             47(1):3955-3960.                               [13]  AGARWAL N,MCPHERSON J P,BAILEY H,et al. A
        [ 2 ]  ATTIA S M,AL-HAMAMAH M A,ALOTAIBI M R,et al.      phase I clinical trial of the effect of belinostat on the phar-
             Investigation of belinostat-induced genomic instability by  macokinetics and pharmacodynamics of warfarin[J]. Can-
             molecular cytogenetic analysis and pathway-focused gene  cer Chemother Pharmacol,2016,77(2):299-308.
             expression profiling[J]. Toxicol Appl Pharmacol,2018,  [14]  ZHANG J H,MOTTAMAL M,JIN H S,et al. Design,
             350(1):43-51.                                       synthesis and evaluation of belinostat analogs as histone
        [ 3 ]  TAKEBE N,BEUMER J H,KUMMAR S,et al. A phase       deacetylase inhibitors[J]. Future Med Chem,2019,11(21):
             Ⅰ pharmacokinetic study of belinostat in patients with ad-  2765-2778.
             vanced cancers and varying degrees of liver dysfunc-  [15]  彭斌,何敏,李正茂,等.贝利司他抑制骨肉瘤细胞活力的
             tion[J]. Br J Clin Pharmacol,2019,85(11):2499-2511.  分子机制[J].中国病理生理杂志,2020,36(3):552-556.
        [ 4 ]  PASSERO F C,RAVI D,MCDONALD J T,et al. Combi-  [16]  赵倩,屈慧新,史慧静,等.治疗复发或难控型外周T细胞
             natorial ixazomib and belinostat therapy induces NFE2L2-  淋巴瘤新药:贝林司他[J].医药导报,2016,35(5):551-
             dependent apoptosis in Hodgkin and T-cell lymphoma[J].  554.
             Br J Haematol,2020,188(2):295-308.             [17]  王娅莉,刘月,班璐,等.非达霉素原料药中有关物质的检
        [ 5 ]  贾文华,毛慧,陈婉如,等.组蛋白去乙酰化酶抑制剂                          查方法研究[J].中国药房,2020,31(5):581-585.
             Belinostat对髓源性树突状细胞免疫功能的作用研究[J].               [18]  雷成康,郭玲. 2015 年版《中国药典》环磷酰胺有关物质
             中华血液学杂志,2018,39(1):41-46.                           检测方法的验证与改进[J].中国药房,2016,27(36):
        [ 6 ]  周付科,郭晓赟,迟丽娜,等.贝利司他药物专利分析[J].                      5122-5124.
             中国新药杂志,2019,28(17):2069-2075.                  [19]  ICH. Impurities in new drug substances:Q3A(R2)[S]. 2006-
        [ 7 ]  ABBOTT K L,CHAUDHURY C S,CHANDRAN A,et al.        10-25.
             Belinostat,at its clinically relevant concentrations,inhi-  (收稿日期:2020-12-29  修回日期:2021-03-30))
             bits rifampicin-induced CYP3A4 and MDR1 gene expres-                                (编辑:邹丽娟)











        ·978 ·   China Pharmacy 2021 Vol. 32 No. 8                                   中国药房    2021年第32卷第8期
   83   84   85   86   87   88   89   90   91   92   93